OMI heads north again

By Dylan Bushell-Embling
Thursday, 31 July, 2008

Occupational and Medical Innovations [ASX: OMI] has found a Canadian distribution partner for its auto-retractable safety syringes.

OMI has granted Domrex Pharma exclusive rights to distribute the syringes in Canada, but OMI's pre-existing deal granting Cardinal Health distribution rights in Canada will still be honoured.

The deal will last three years, and will be extended if minimum sales targets are met.

The safety syringes have yet to be approved for sale in Canada, but OMI expects to obtain regulatory approvals in late August or early September.

OMI announced yesterday that the Federal Court of Australia had found that its syringe device did not infringe the patent of US competitor Retractable Technologies (RTI).

RTI is also suing Becton Dickinson (BD) in the US for patent infringement.

Related News

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd